MGI Tech Co., Ltd. (referred to as MGI) is committed to building core tools and technology to lead life science through intelligent innovation. With a focus on R&D, production and sales of DNA sequencing instruments, reagents, and related products, MGI provides real-time,
panoramic, and full-life-cycle equipment and systems for precision medicine, precision healthcare and other relevant areas.
MGI is a leading producer of clinical high-throughput gene sequencers, and
its multi-omics platforms include genetic sequencing, medical imaging, and laboratory automation.
Beijing GenePlus Technology Co., Ltd.
Beijing GenePlus Technology Co., Ltd (referred to as Gene+) was founded in 2015 and has since equipped next-generation sequencing (NGS) clinical laboratories and genetic institutes in Beijing, Suzhou and Shenzhen. Gene+ is a leading supplier for oncology and precision medicine in China. The Gene+ all-in-one solution utilizing MGI’s DNBSEQ platforms in Oncology has already been deployed in more than 30 key hospitals in China and is becoming a leader in the clinical application of NGS.
Together we provide expert oncology solutions to NGS users
Available assays include a Oncology 59-Gene Variant Assay and a Oncology Multi-Gene Variant Assay (1021-Gene) which have been validated on the DNBSEQ-G400 using HotMPS sequencing chemistry.
* This sequencer is only available in selected countries, and its software has been specially configured to be used in conjunction with MGI’s HotMPS sequencing reagents exclusively.
**This sequencing reagent is only available in selected countries.